FOLH1 and prostate carcinoma: We have previously shown that encapsulation of EGCG into polymeric blended nanosystems, targeted with small molecules capable of binding to the prostate-specific membrane antigen, enhances the antiproliferative activity of EGCG in prostate cancer both in vitro and in vivo [32].